Repligen Corp
(MIL:1RGEN)
€
121.6
(0%)
Market Cap: 7.05 Bil
Enterprise Value: 6.97 Bil
PE Ratio: 158.22
PB Ratio: 3.81
GF Score: 61/100 Repligen Corp at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 26, 2021 / 05:00PM GMT
Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst
Okay. Great. Welcome, everyone. I'm Puneet Souda, SVB Leerink tools and diagnostic analyst here. And it's a pleasure to be hosting Repligen management team. Joining us from Repligen is Tony Hunt, CEO; and Jon Snodgres, CFO. Hey guys, welcome. Glad to have you here.
Anthony J. Hunt
Repligen Corporation - CEO, President & Director
Puneet, good to see you.
Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst
Great. So just before we get started, I mean, to me, look, Repligen is a high-growth company in the bioprocessing space that is benefiting COVID vaccine ramp and is increasingly seeing growth from high-growth markets of cell and gene therapy. So obviously, a lot to cover here. Please send me questions through the chat if you have any or through e-mail, and we'll cover them during the session.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot